The Medicines Company sells its infectious diseases business to Melinta Therapeutics which includes Vabomere,Orbactiv and Minocin IV.

The Medicines Company announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. for $270 million in upfront consideration and guaranteed payments ($215 million of guaranteed cash and $55 million of Melinta common stock), tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere, Orbactiv and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products. Vabomere is The Medicines Company's newest product which secured FDA approval in August 2017 to treat complicated urinary tract infections